INTRODUCTION
Invasive meningococcal disease (IMD) is a serious systemic disease caused by the strict human pathogen Neisseria meningitidis. Most invasive N. meningitidis possess a polysaccharide capsule, which is a well-known virulence factor and a protective antigen. Based on the unique antigenic specificities of the capsules, N. meningitidis is divided into at least 12 different serogroups, and globally, most invasive diseases are caused by strains that belong to serogroups A, B, C, Y and W (Vedros, 1987) , and more recently also serogroup X, in the African continent (Xie et al., 2013) . Although capsular polysaccharide vaccines against serogroups A, C, Y and W meningococci were introduced decades ago, and the conjugated capsule vaccine against serogroup C meningococci (MenC) more than a decade ago, IMD is still a serious disease. With routine infant and adolescent MenC conjugated vaccine immunization programs introduced in the UK (Miller et al., 2001) and Canada (Warshawsky et al., 2009) , incidences of MenC diseases in these countries have reduced substantially, and the remaining IMD is now mostly caused by serogroup B (MenB) strains. Unlike serogroups A, C, Y (MenY) and W (MenW), the capsule of MenB is not immunogenic, since it cross-reacts with a self-component (Finne et al., 1983) , and is therefore, not a suitable vaccine candidate (Lewis et al., 2009 ).
To control outbreaks of MenB IMD, outer membrane vesicle (OMV) vaccines have been used (Bjune et al., 1991; Sierra et al., 1991; de Moraes et al., 1992; Oster et al., 2005) , but these are strain specific and thus only active against strains with PorA antigens identical to the PorA present in the OMV vaccine. Intense research in the last decade using newer technologies has led to the recent development of a number of newer MenB vaccines, which may have the potential of being broadly protective against MenB or multiple serogroups and strains of N. meningitidis (Granoff, 2010) . One such vaccine is the multi-component recombinant vaccine 4CMenB (Santolaya et al., 2012) , which is made up of three major proteins [factor H binding protein (fHbp) subfamily B or Novartis variant 1.1, Neisseria heparinbinding antigen (NHBA) peptide 2 and Neisseria adhesin A (NadA)-3.8] and the OMV vaccine prepared from the MenB strain NZ98/254 (B:4:P1.7-2,4; ST-42; PorA P1.7-2,4) that was used to control the MenB epidemic in New Zealand (Oster et al., 2005) . Three subvariants (variants 1, 2 and 3) or two subfamilies (A equivalent to subvariants 2 and 3; B equivalent to subvariant 1) of fHbp exist, and extensive cross-reactions within a subfamily of proteins suggest crossprotection is possible within a subfamily but not between subfamilies (Masignani et al., 2003) . NHBA peptides have also been reported to provide cross-protection to cover multiple different peptide types (Giuliani et al., 2006) . Among the five NadA peptide types, NadA-1, 2 and 3 crossreact and thus allow for potential cross-protective ability (Comanducci et al., 2002) . The other MenB vaccine in advanced clinical trials is a bivalent fHbp protein vaccine made up of a representative protein from each of the subfamilies of A (peptide ID A45 that is the equivalent to Novartis variant 3.45) and B (peptide ID55 that is the equivalent to Novartis variant 1.55) (Murphy et al., 2009; Richmond et al., 2012) .
In preparation of the potential introduction of these newer meningococcal vaccines, the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC) in collaboration with the provincial public health laboratories have been characterizing invasive MenB strains recovered from IMD cases residing in the two most populous provinces in Central and Eastern Canada; Ontario (Jamieson et al., 2013) and Quebec . Despite being neighbouring provinces, the epidemiology of MenB IMD in these two provinces is quite different Dang et al., 2012) , as was reflected in the characteristic of their invasive MenB strains Jamieson et al., 2013) .
In this study, we characterized invasive N. meningitidis strains recovered from IMD cases in four western Canadian provinces (British Columbia, Alberta, Saskatchewan and Manitoba) during the period of 2009 to 2013. We examined the expression of their serogrouping, serotyping and serosubtyping antigens, their clonal biology and genetic sequence of the 4CMenB vaccine antigens in them. In this manuscript, we describe the findings and compare them with data from other similar studies.
METHODS
Bacterial isolates. One hundred and sixty-one invasive N. meningitidis isolates recovered from individual IMD cases in the four western provinces in Canada were included in this study. The isolates were received at the NML from January 1, 2009 to December 31, 2013. As such, some isolates received at the beginning of January 2009 may have been from cases in late 2008. Similarly, a few isolates that happened in late 2013 may not have been received at the NML by December 31, 2013. Also, only culture-positive isolates recovered from normally sterile body sites of suspected IMD cases were included. Therefore, the number of cases identified by culture alone was lower than the total number of cases, including those confirmed by PCR.
Serogrouping, serotyping and serosubtyping. The serogroup was determined at the provincial public health laboratories and confirmed at the NML using bacterial agglutination test with rabbit serogrouping antisera (Riou & Guibourdenche, 1992) . Isolates that were negative by bacterial agglutination test or auto-or poly-agglutinable were tested by PCR with primers specific for serogroups A, B, C, Y, W, X, Z and E (Borrow et al., 1997 (Borrow et al., , 1998 Taha, 2000; Bennett et al., 2004) .
Serotyping and serosubtyping were performed at the NML by indirect whole cell ELISA (Abdillahi & Poolman, 1987) MLST was performed according to the method described by Maiden et al. (1998) , and sequence type (ST) was assigned according to the Neisseria MLST website (http://neisseria.org/nm/typing/mlstdb/). PorA genotyping was done by sequencing the variable regions of porA genes according to methods described previously (Sacchi et al., 1998; Clarke et al., 2003) . PorA genotypes were described according to nomenclatures schemes in the Neisseria PorA VR database (http://pubmlst.org/ neisseria/PorA/), and as described by de Filippis et al. (2011) .
DNA sequencing of 4CMenB vaccine antigen genes. MenB vaccine antigen genes (fHbp, nhba and nadA) were PCR amplified and sequenced according to methods described by Lucidarme et al. (2010) . The fHbp, nhba and nadA genotypes and their predicted peptide types were analysed and interpreted based on the online sequence typing tool provided by the Neisseria MLST website (http://pubmlst.org/neisseria).
RESULTS

Serogroup distribution
One hundred and sixty one N. meningitidis isolates were collected from individual IMD cases from 2009 to 2013, of which 69 (42.9 %) belonged to MenB, 47 (29.2 %) MenY, 22 (13.7 %) MenC, 19 (11.8 %) MenW, while 4 (2.5 %) belonged to other serogroups (three were serogroup E and one was non-encapsulated). The distribution of invasive N. meningitidis serogroups in the four western provinces in Canada is described in Table 1 .
Population genetics of invasive N. meningitidis in Western Canada
Invasive MenC, MenY and MenW were each dominated by a separate clonal complex (cc), cc11 for MenC, cc23 for MenY and cc22 for MenW, which accounted for 86.4, 63.8 and 89.5 % of the isolates in these three serogroups, respectively. In contrast, invasive MenB isolates belonged to eight different clonal complexes and none appeared to be predominant. There were also 11 (15.9 %) MenB case isolates that did not belong to any assigned cc (Table 2) . A total of 62 unique STs were identified, with 40 found in MenB, three in MenC, nine in MenY, six in MenW, three in serogroup E and one in the non-encapsulated strain.
Serotype and serosubtype antigens
There were 10 different presentations of serotype antigens among the 161 invasive N. meningitidis isolates, listed in order of decreasing frequencies: 2c (n524); 19 (n522); 2a (n520); 1,19 (n517); 4 (n515); 14,19 (n515); 17 (n57); 15 (n56); 15,19 (n53) and 1 (n51). Thirty-one isolates were non-serotypable. Serotype 2c was found exclusively in MenY, while serotypes 4; 1,19; and 17 were only found in MenB. Serotype 2a was almost exclusively found in MenC with the exception of its presence in one MenW isolate. Serotype 19 and serotype 14,19 were found in both MenB and MenY isolates; these serotypes were also found in one MenC isolate and in one MenW isolate.
Seventeen different combinations of serosubtype antigens were found. The five most common serosubtype antigens were P1.5,2 (n529); P1.14 (n523); P1.5 (n522); P.1.4 (n59); and P1.6 (n58). Together these five serosubtype antigen combinations were found in 56.5 % of the isolates. Forty isolates did not express detectable serosubtype antigens.
There were 47 different combinations of serotype:serosubtype antigens in the 161 invasive N. meningitidis isolates. The most common antigenic formulas were 2a:P1.5,2 (n514; 13 were MenC); 1,19:P1.13 (n513; all were MenB); 2c:P1.5 (n512; all MenY); 2c:P1.5,2 (n511; all were MenY); 4:P1.4 (n58; all MenB); and NT:P1.6 (n57; all MenW). There were also 22 antigenic types that occurred only once (i.e. found in only single isolates); eight antigenic types that occurred only twice (i.e. two isolates per antigenic type); three antigenic types with three isolates per type; six antigenic types with four isolates each; and three antigenic types with six isolates each. Only eight isolates did not express detectable serotype and serosubtype antigen.
PorA genotype
There were 47 different PorA genotypes identified, but 24 types occurred only once and 10 types occurred only twice. Ten PorA genotypes: P1.5-1,10-4,36-2 (n518); P1.22,14,36 (n516); P1.5,2,36-2 (n515); P1.5-1,2-2,36-2 (n513); P1.18-1,3,38 (n511); P1.5-2,10-1,36-23 (n510); P1.7-2,4,37 (n58); P1.22, 14-6, 36-2 (n55); P1. 22-1,14,36 (n54); and P1.19-1,15-11,36 (n54) were found in 104 (64.6 %) isolates.
4CMenB vaccine antigen genes
Of the 161 invasive N. meningitidis isolates, only 10 expressed PorA serosubtype antigen P1.4 and carried the PorA genotype of P1.7-2,4. All 10 isolates were serogroup B; 9 belonged to cc41/44 with five isolates of ST-154; one isolate each of ST-5550, ST-9171, ST-9352, ST-10347 and one isolate of ST-162 (162 cc).
Thirty-two (19.9 %) of the 161 invasive N. meningitidis isolates were found to have fHbp genes predicted to encode subfamily B (Novartis variant 1) fHbp; 109 (67.7 %) isolates were predicted to produce subfamily A (Novartis variant 2) fHbp, and 19 (11.8 %) isolates with genes that would encode subfamily A (Novartis variant 3) fHbp. One MenC isolate was found to have a single nucleotide deletion in its fHbp gene at position 336 that led to a frame shift and a pre-mature stop codon in its coding sequence; therefore, no fHbp was expected to be expressed from this strain (Lucidarme et al., 2011) . All MenY and all but one MenW were found to contain only fHbp genes that would encode variant 2 or subfamily A peptides. In contrast, MenB isolates were found to encode all three variants of fHbp, with 37.7, 34.8 and 27.5 % carrying genes that encoded the Novartis variants 1, 2 and 3 fHbp, respectively (Fig. 1) . The three serogroup E and the single nonencapsulated meningococci contained fHbp genes for Novartis variant 1 proteins. There were only two isolates with fHbp genes that encode variant 1.1 protein and both belonged to cc32. Altogether 32 isolates were predicted to produce subfamily B (Novartis variant 1) fHbp, and they included 26 MenB, one MenC, one MenW, three serogroup E and the non-encapsulated isolate. One hundred and twenty-two (76 %) of the invasive N. meningitidis did not have a nadA gene. Thirty-nine isolates had a nadA gene, but in 14 isolates their nadA genes were either disrupted by an insertion sequence or a pre-mature stop codon leading to no protein expected to be produced. Only 25 isolates were likely to produce a NadA protein. The distribution of nadA genes and the predicted peptides found among the different serogroups is described in Table 3 .
All 161 invasive N. meningitidis isolates were found to contain nhba genes and 31 different NHBA peptide types were predicted from them. Despite this diversity, nine peptide types (peptides 2, 6, 7, 8, 9, 18, 20, 21 and 29) were predicted in 122 (75.8 %) isolates that have genes encoding them. The distribution of NHBA peptide types among the different serogroups of invasive N. meningitidis can be found in Table 4 . Table 5 shows the predicted 4CMenB vaccine antigens in 107 invasive N. meningitidis isolates belonging to common STs. Although some correlations existed between certain STs and the predicted 4CMenB vaccine antigens found in them, the correlation was seldom absolute. Also, more extensive variations were found among isolates in cc32.
Based on determination of the 4CMenB vaccine antigen genes, no isolate was found to produce antigens that would match all four or three of the four vaccine components, i.e. PorA P1.4; fHbp variant 1.1; NHBA peptide 2; and NadA-1, 2, or 3. Only seven (4.4 %) isolates were found to have 4CMenB vaccine antigen genes that encoded two matching vaccine components (six cc41/44 isolates with PorA P1.4 and NHBA-2, and one cc32 isolate with fHbp variant 1.1 and NadA-1). , an ST known to be associated with the cnl phenotype and in particular the cnl-2 allele (Claus et al., 2002) . IMD cases due to cnl-2 strains typed as had been reported in the Canadian provinces of British Columbia (Hoang et al., 2005) and Ontario (Johswich et al., 2012) . Therefore, with increasing use of meningococcal vaccines, whether these rare serogroups or non-groupable/non-encapsulated N. meningitidis strains will gain more prevalence as causes of IMD would require continued surveillance in the post conjugate and newer protein-based vaccine era (Bettinger et al., 2013b) .
Clonal analysis of MenB from Western Canada revealed a heterogeneous population with no single clone or ST predominating, suggesting a picture of endemic MenB disease. Among the five most common ccs found in Western Canada, four (cc41/44, cc269, cc32 and cc35) were also common in the province of Ontario and Quebec (Jamieson et al., 2013; Zhou et al., 2012) , and were also listed among their five most common ccs found in these central and eastern provinces. In Western Canada, 17.3 % of their MenB belonged to cc213. In contrast, this cc represented only 0.89 % (n52) of the MenB in Quebec ) and 1.0 % (n53) of the MenB in Ontario (Jamieson et al., 2013) . Although the Quebec ST-269 clone (Law et al., 2006; Zhou et al., 2012) was present in Western Canada, like in Ontario (Dang et al., 2012; Jamieson et al., 2013) , it was only responsible for a very small number of MenB cases. Both cc213 and cc269 have been described as recently emerged clones (Bambini et al., 2009) , and therefore their spread and evolution warrant careful monitoring. Invasive N. meningitidis in Western Canada, 2009 Unlike MenB, most of the MenC invasive isolates belonged to ST-11 (Table 2) , which has been the predominant MenC clone in Canada since the early 1990s (Ashton et al., 1991) . In this study, we also detected for the first time in Canada a MenC case in British Columbia that was due to a strain typed as ST-4821, which has been reported to be an emerging new clone of MenC in China in -2004 (Shao et al., 2006 . This unusual MenC isolate harboured 4CMenB antigen genes that predicted fHbp peptide 2.22 (Novartis variant 2 or subfamily A), NHBA peptide 503 and no NadA protein due to an absence of the nadA gene.
In Western Canada, most of the invasive MenY were grouped into two cc, cc23 and cc167, which were responsible for 63.8 and 19.2 % of the 47 MenY isolates examined, (1) 1 (1) 5 (1) NadA-1, peptide 1 (1) 54 (1) 5 (1) NadA-1, peptide 1 (1) 224 (1) 3 (1) NadA-1, peptide 100 (1) (1) 7 (1) Truncated, allele 12 (1) 45 (1) 29 (1) Truncated, allele 12 (1) 29 (13) NadA-2/3, peptide 3 (13) 22 (1) 29 (1) NadA-2/3, peptide 121 (1) 22 (1) 29 (1) None, frame-shift, allele 3 (1) 201 (2) 29 (2) NadA-2/3, peptide 3 (2) 25 (1) 20 (1) NadA-2/3, peptide 3 (1) Allele 669 (1) 20 (1 (1) 20 (1) Absent (1) 25 (1) 21 (1) Absent (1) 25 (2) 308D (2) Absent (2) (Ashton & Caugant, 2001 ) as opposed to MenC, MenY and MenW, which appeared to be more clonal (Table 5) . When compared to data from another earlier study in Canada on 4CMenB vaccine antigens in MenB collected from a national study by Immunization Program Active (IMPACT), which is a national surveillance system based on 12 tertiary care hospitals in eight provinces and covers slightly more than 50 % of the Canadian population (Bettinger et al., 2013a) , this study involving invasive N. meningitidis from Western Canada came up with several important differences. Among the invasive MenB in Western Canada, cc213 was responsible for 12 of 69 isolates or 17.4 %, while there were only two (1.3 %) such isolates in the IMPACT study. While the majority (100 isolates or 63.7 %) of the MenB isolates in the IMPACT study were determined to have fHbp that belonged to variant 1 (subfamily B), only 37.7 % of the MenB in Western Canada were predicted to produce variant 1 fHbp. Also 27.5 % (19 of 69 isolates) of the MenB from Western Canada were predicted to produce variant 3 fHbp, and only 7 % (11 of 157 isolates) of the IMPACT MenB were found to be positive for variant 3 fHbp. Of the 19 MenB isolates in Western Canada that were positive for variant 3 fHbp genes, 11 isolates belonged to cc213 and predicted to express fHbp peptide 3.45 (data not shown). The difference in the fHbp peptide types in these two Canadian studies might be related to the higher number of ST-269 isolates from Quebec captured in the IMPACT study, which uniformly have fHbp peptide 1.15 (Bettinger et al., 2013a ).
This ST was not common in Western Canada, while cc213 that has fHbp genes for variant 3.45 fHbp was more common. Fourteen (8.9 %) MenB from the IMPACT study were found to have the nhba gene that encoded NHBA peptide 112; this NHBA peptide was absent from the invasive N. meningitidis isolates from Western Canada. On the contrary, 13 % (9 isolates) of the MenB from Western Canada were positive for the nhba gene that encoded NHBA peptide 18, which was found in fewer than five isolates (less than 3.2 %) of the MenB from the IMPACT study.
Based on DNA sequencing of the fHbp genes in the USA, 30 % of the MenB were predicted to be positive for fHbp variant 1.1 (Wang et al., 2011) . In Western Canada, only 2.9 % or two isolates were positive for the fHbp variant 1.1 gene. In a number of European countries, the percentage (65.2 to 76.7 %) of MenB isolates with fHbp genes for subfamily B or variant 1 peptide were consistently higher than the per cent (23.3 to 34.8 %) of isolates with fHbp genes for subfamily A or variant 2-3 fHbp (Murphy et al., 2009) . In the UK common fHbp peptide types were 1.4 and 1.15 (23.5 and 22.0 %, respectively). In France, common fHbp peptide types were 1.14, 1.1 and 2. 19 (22.5, 19.7 and 12.7 %, respectively) . In Western Canada, common fHbp peptide types were 3.45, 1.4, 1.14 and 2.19 (15.9, 13.0, 7.3 and 7.3 %, respectively). Also the MenB isolates in Western Canada appeared to harbour more diverse fHbp types compared to that found in the USA, UK and France (Wang et al., 2011; Murphy et al., 2009 ).
When assessed on 11 April 2014, the Neisseria sequence typing website page listed 43 different NadA peptide types with 96 alleles, 381 alleles that encode 270 NHBA peptide types and 863 alleles that encode 707 fHbp peptide types (http://pubmlst.org/neisseria). Mutations that disrupted the vaccine antigen genes leading to no vaccine antigens expressed have also been described (Lucidarme et al., 2011; Wang et al., 2011) . Therefore, with the natural evolution of strains and the potential immune selection pressure from the use of protein-based vaccines in the future, the variability of these vaccine antigens may further increase and potentially jeopardize the strain coverage. Therefore, in the post-polysaccharide conjugated and protein-based vaccine era, surveillance of IMD would require monitoring changes in the serogroups of invasive N. meningitidis as well as molecular and phenotypic typing to measure expression and genetic diversity of the protein vaccine antigens.
One major limitation of this study was we did not measure expression of the 4CMenB vaccine antigens or vaccine coverage of our strains based on the amount of crossreactivities between antigens in the clinical isolates and antigens in the vaccine. Only by such studies can vaccine strain coverage be estimated. 
